Key facts
- This page summarizes Stacy Markel's Form 4 filing for Nuvation Bio Inc. (NUVB).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jun 2026, 19:09.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
Footnote F2
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
Footnote F4
Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date.